Biotechnology has led to the development of many of the most advanced therapies for cancer, infections, and Alzheimer’s Disease, and is at the forefront of renewable energy technologies. The combination of biotechnology and pharmaceuticals with diagnostics is the basis for the success of Personalized Medicine approaches, the future of medical treatment, including immunotherapy. As both an experienced scientist and IP attorney, Dr. Carla Mouta-Bellum has worked closely with many academic scientists and companies in these fields and has more than 12 years of experience developing strong and diverse patent portfolios and counseling clients in IP matters. Prior to joining Arrigo, Lee, Guttman & Mouta-Bellum LLP, Carla spent 12 years at Finnegan preparing and prosecuting patent applications before the U.S. and foreign patent offices and counseling clients on intellectual property strategies, due diligence acquisitions, freedom to operate, non-infringement, and validity opinions. Carla’s understanding of the critical scientific issues underlying each invention and its patentability comes, in large part, from the more than 13 years spent in academia, including her experience as a post-doctoral fellow at Harvard and a Principal Investigator on NIH-funded grants at the Maine Medical Center Research Institute. Carla has published and lectured frequently on diagnostics and immunotherapy-related strategies and challenges.